H3 receptor antagonists/inverse agonists as anti-obesity agents.
The role of histamine in a variety of central nervous system functions is emerging as increasingly complex, with known effects on behavioral and homeostatic functions. With the discovery of presynaptic H3 receptors and the identification of novel ligands for these sites, new pharmacological data suggest a potential role for H3 antagonists and/or inverse agonists in the control of feeding, appetite and body weight. The in vitro and in vivo attributes of these compounds support the prospect that one of the new lead agents currently under preclinical investigation will have the properties required for clinical utility as an anti-obesity agent.
Hancock
Arthur A
AA
Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064-6125, USA. Art.A.Hancock@Abbott.com
D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004435:Eating / Q000502:physiology; D006632:Histamine / Q000378:metabolism / Q000502:physiology; D017442:Histamine Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D006633:Histamine Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D018377:Neurotransmitter Agents / Q000378:metabolism / Q000502:physiology; D018100:Receptors, Histamine H3 / Q000187:drug effects* / Q000378:metabolism
D019440:Anti-Obesity Agents; D017442:Histamine Agonists; D006633:Histamine Antagonists; D018377:Neurotransmitter Agents; D018100:Receptors, Histamine H3; D006632:Histamine